Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niels Heersche

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 27, 2025
Response to Letter Re: Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levelsNiels Heersche, Ron H J Mathijssen, Annemieke Cats, et al.
Clinical Chemistry and Laboratory Medicine|July 18, 2024
Is uracil enough for effective pre-emptive DPD testing?Niels Heersche, Maja Matic, Ron H J Mathijssen, et al.
Cancer Treatment Reviews|December 3, 2023
Review - The impact of pharmacogenetics on the outcome of immune checkpoint inhibitorsKarlijn de Joode, Niels Heersche, Edwin A Basak, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 15, 2022
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancerNiels Heersche, G D Marijn Veerman, Mirjam de With, et al.
Clinical Pharmacology and Therapeutics|October 16, 2021
Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover TrialLeni van Doorn, Niels Heersche, Femke M de Man, et al.
Genes|April 2, 2020
Influence of Genetic Variation in <i>COMT</i> on Cisplatin-Induced Nephrotoxicity in Cancer PatientsBram C Agema, Stijn L W Koolen, Mirjam de With, et al.
JCO Precision Oncology|June 8, 2026
Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A <i>DPYD</i> Variant AlleleNiels Heersche, Jonathan E Knikman, Maarten J Deenen, et al.
Cancer Communications (London, England)|May 1, 2025
Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction studyNiels Heersche, Daan A C Lanser, Esther Oomen-de Hoop, et al.
Frontiers in Pharmacology|December 3, 2021
Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal CancerRuben A G van Eerden, Leni van Doorn, Femke M de Man, et al.
Cancer Communications (London, England)|May 25, 2026
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with <i>ALK-</i>Positive Non-Small Cell Lung CancerDaan A C Lanser, Niels Heersche, M Benthe Muntinghe-Wagenaar, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
European Journal of Cancer (Oxford, England : 1990)|September 27, 2025
Response to Letter Re: Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levelsNiels Heersche, Ron H J Mathijssen, Annemieke Cats, et al.
Clinical Chemistry and Laboratory Medicine|July 18, 2024
Is uracil enough for effective pre-emptive DPD testing?Niels Heersche, Maja Matic, Ron H J Mathijssen, et al.
Cancer Treatment Reviews|December 3, 2023
Review - The impact of pharmacogenetics on the outcome of immune checkpoint inhibitorsKarlijn de Joode, Niels Heersche, Edwin A Basak, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 15, 2022
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancerNiels Heersche, G D Marijn Veerman, Mirjam de With, et al.
Clinical Pharmacology and Therapeutics|October 16, 2021
Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover TrialLeni van Doorn, Niels Heersche, Femke M de Man, et al.
Genes|April 2, 2020
Influence of Genetic Variation in <i>COMT</i> on Cisplatin-Induced Nephrotoxicity in Cancer PatientsBram C Agema, Stijn L W Koolen, Mirjam de With, et al.
JCO Precision Oncology|June 8, 2026
Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A <i>DPYD</i> Variant AlleleNiels Heersche, Jonathan E Knikman, Maarten J Deenen, et al.
Cancer Communications (London, England)|May 1, 2025
Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction studyNiels Heersche, Daan A C Lanser, Esther Oomen-de Hoop, et al.
Frontiers in Pharmacology|December 3, 2021
Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal CancerRuben A G van Eerden, Leni van Doorn, Femke M de Man, et al.
Cancer Communications (London, England)|May 25, 2026
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with <i>ALK-</i>Positive Non-Small Cell Lung CancerDaan A C Lanser, Niels Heersche, M Benthe Muntinghe-Wagenaar, et al.
Pageof 2